Health Condition 1: R978- Other abnormal tumor markers
Conditions
Interventions
Intervention1: NA: NA
Control Intervention1: NA: NA
Sponsors
Novartis Healthcare Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: Written patient informed consent must be obtained prior to any data collection and sample shipment to a local designated laboratory. 2. Patient is an adult male or female (= 18 years of age). 3. Confirmed advanced (locoregionally recurrent not amenable to curative therapy or metastatic) breast cancer. 4. Patient has a histologically and/or cytologically confirmed diagnosis of ER+ and/or PgR+ , as well as Her2- breast cancer by local laboratory. 5. Patient has available a tumor tissue (archival or fresh) to be sent to a local lab for PIK3CA testing. 6. Any lines of treatment for metastatic setting will be allowed.
Exclusion criteria
Exclusion criteria: Non applicable
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To describe the frequency of PIK3CA mutations in men and women with HR+ HER2- advanced breast cancer.Timepoint: 1 year | — |
Secondary
| Measure | Time frame |
|---|---|
| To explore the relationship between PIK3CA status and clinical outcomes in the advanced setting.Timepoint: 1 year;To characterize treatment patterns in the advanced setting among ABC patients,by PIK3CA mutation status.Timepoint: 1 year | — |
Countries
Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Egypt, France, Greece, Hong Kong, Hungary, India, Italy, Jordan, Kuwait, Latvia, Lebanon, Malaysia, Mexico, Netherlands, Qatar, Republic of Korea, Russian Federation, Saudi Arabia, Singapore, Switzerland, Taiwan, Thailand, Turkey, United Arab Emirates, United Kingdom
Contacts
Public ContactMurugananthan K
Novartis Healthcare PVT LTD
Outcome results
None listed